AtaiBeckley Inc. (ATAI)
Summary
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by advancing clinical data and an improving regulatory backdrop. The acquisition, previously announced by Lilly, values AtaiBeckley at $6.75 per share in cash, or about $2.8 billion in equity, plus a contingent value right of up to $2.50 per share, worth roughly $1 billion if certain milestones are achieved.
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026.
AtaiBeckley Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 50 | $205 | $275.88 | $70.88 | 34.58% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 200 | $708 | $1,087 | $379 | 53.53% |
 Point72 Asset Management LP Point72 Asset Management LP | 664,724 | $2.35M | $3.56M | $1.21M | 51.27% |
 Ruane Cunniff & Goldfarb LP Ruane Cunniff & Goldfarb LP | 42,112 | $149,076 | $228,878.72 | $79,802.72 | 53.53% |
| NM Nir Messafi Deep Track Capita LLP | 12M | $42.48M | $64.68M | $22.2M | 52.26% |
AtaiBeckley Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EH Eddie Hickman Guggenheim | 7.63M | $30.59M | $40.87M | $10.28M | 33.61% |
AtaiBeckley Inc. (ATAI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AtaiBeckley Inc. ever had a stock split?
AtaiBeckley Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Christian Angermayer CEO | NASDAQ (NMS) Exchange | 04650F101 CUSIP |
| US Country | 99 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Atai Life Sciences N.V. is a pioneering clinical-stage biopharmaceutical company aimed at revolutionizing the treatment of mental health disorders including depression, anxiety, addiction, and more. Established in 2018, with its roots in Berlin, Germany, and with additional offices in New York and London, Atai Life Sciences is pushing the boundaries of traditional mental health treatment modalities by investing in and developing a wide array of therapeutics. Their mission extends towards addressing the unmet needs in mental health care through a strongly differentiated and diversified portfolio of treatments, embarking on a journey to mitigate the global mental health crisis.
Products and Services
- COMP360 (Psilocybin)
- BPL-003 (Intranasal Formulation)
- TRD
- VLS-01
- ELE-101
- IBX-210
- DMX-1002
- EMP-01
- EGX-A and EGX-B
- RL-007
- GRX-917
- PCN-101 (R-Ketamine)
- KUR-101 (Deuterated Mitragynine)
- RLS-01
A proprietary formulation of psilocybin, currently in a Phase 3 clinical program, focusing on its potential therapeutic effects for mental health disorders.
An innovative intranasal formulation of betahistine in active Phase 2a and 2b clinical studies aimed at treating vertigo with lesser side effects and improved patient outcomes.
A therapeutic under development, details unspecified, targeting treatment-resistant depression.
A transmucosal film in Phase 1b clinical studies targeted at delivering therapeutic agents effectively for mental health conditions.
A serotonergic psychedelic in Phase 1/2a study aimed at treating treatment-resistant depression, showcasing the potential of psychedelics in mental health therapy.
An intravenous formulation of ibogaine under development for treating opioid use disorder, addressing the critical need for effective addiction therapies.
An oral formulation of ibogaine indicated for the treatment of opioid use disorder, exploring a different administration route for ibogaine's therapeutic effects.
An oral formulation of an R-MDMA derivative being developed for post-traumatic stress disorder, expanding the therapeutic options for PTSD.
Psychotropic substances with novel, non-tryptamine structures offering differentiated 5-HT receptor pharmacology, aiming at unique mental health treatment pathways.
An orally bioavailable compound acting as a pro-cognitive neuromodulator, under investigation for the cognitive impairment associated with schizophrenia.
A deuterated version of etifoxine designed for the treatment of generalized anxiety disorder, highlighting an approach to minimize anxiety with potentially reduced side effects.
A subcutaneous formulation of R-ketamine focused on psychiatric indications initially targeting treatment-resistant depression, demonstrating the therapeutic versatility of ketamine.
A formulation of deuterated mitragynine under development for the treatment of opioid use disorder, reflecting on the need for innovative addiction treatments.
Indicated for treatment-resistant depression, RLS-01 represents Atai's dedication to finding solutions for those who haven't responded to existing treatments.
